Granulocyte-macrophage colony stimulating factor biosimilar - North China Pharmaceutical Corporation

Drug Profile

Granulocyte-macrophage colony stimulating factor biosimilar - North China Pharmaceutical Corporation

Alternative Names: HUABEI JIMUXIN; Jimuxin; rhGM-CSF - North China Pharmaceutical Corporation

Latest Information Update: 30 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator North China Pharmaceutical Corporation
  • Developer North China Pharmaceutical Corporation; Peking Union Medical College Hospital
  • Class Adjuvants; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Leucopenia
  • Phase II Pulmonary alveolar proteinosis

Most Recent Events

  • 30 Dec 2016 Granulocyte-macrophage colony stimulating factor biosimilar is still in phase II trials for Pulmonary alveolar proteinosis in China (Inhalation)
  • 26 Sep 2014 Launched prior to this date for Leucopenia (Chemotherapy-induced) in China (SC)
  • 26 Sep 2014 Launched prior to this date for Leucopenia (Radiotherapy-induced) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top